Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Rudolf Foundation Clinic |
---|---|
Information provided by: | Rudolf Foundation Clinic |
ClinicalTrials.gov Identifier: | NCT00569569 |
The treatment of fibrotic choroidal neovascular lesions with presence of residual peripheral activity in age related macular degeneration currently presents a great challenge. With visual loss threatening, there are only very few therapeutic options.
While these patients are neither suitable for laser therapy nor for photodynamic therapy with Verteporfin, antiangiogenic drugs applied intravitreally are now available.
Some patients however reject this therapeutic option because of potential complications such as endophthalmitis and the frequency of necessary injections. 20 patients who rejected intravitreal therapy were treated with Anecortave acetate (Retaane®) which was applied as a juxtascleral depot injection.
Condition | Intervention | Phase |
---|---|---|
Age Related Macular Degeneration |
Drug: juxtascleral depot injection of Retaane |
Phase II Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment |
Official Title: | Retaane® in Age-Related Macular Degeneration |
Enrollment: | 20 |
Study Start Date: | February 2006 |
Study Completion Date: | March 2007 |
Arms | Assigned Interventions |
---|---|
1: Experimental
Patients treated with Retaane
|
Drug: juxtascleral depot injection of Retaane
juxtascleral depot injection of Retaane
|
Ages Eligible for Study: | 20 Years to 90 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | RFC012007 |
Study First Received: | December 5, 2007 |
Last Updated: | December 6, 2007 |
ClinicalTrials.gov Identifier: | NCT00569569 |
Health Authority: | Austria: Ethikkommission |
Eye Diseases Retinal Degeneration Macular Degeneration Retinal Diseases Retinal degeneration |